Ocugen, Inc. (OCGN)
Largest Insider Buys in Sector
OCGN Stock Price History Chart
OCGN Stock Performance
About Ocugen, Inc.
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development …
Insider Activity of Ocugen, Inc.
Over the last 12 months, insiders at Ocugen, Inc. have bought $0 and sold $0 worth of Ocugen, Inc. stock.
On average, over the past 5 years, insiders at Ocugen, Inc. have bought $482,227 and sold $9.67M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 200,278 shares for transaction amount of $99,999 was made by Zhang Junge (director) on 2023‑06‑14.
List of Insider Buy and Sell Transactions, Ocugen, Inc.
| 2023-06-14 | director | 200,278 0.0886% | $0.50 | $99,999 | +8.98% | |||
| 2023-02-16 | Sale | Chief Executive Officer | 100,000 0.046% | $1.08 | $108,000 | -49.12% | ||
| 2023-01-17 | Sale | Chief Executive Officer | 100,000 0.045% | $1.28 | $128,000 | -56.90% | ||
| 2022-12-16 | Sale | Chief Executive Officer | 95,809 0.0407% | $1.43 | $137,007 | -62.61% | ||
| 2022-10-14 | Sale | Chief Executive Officer | 100,000 0.0484% | $1.66 | $166,000 | -49.17% | ||
| 2022-10-06 | Sale | director | 4,500 0.0021% | $1.83 | $8,235 | -54.28% | ||
| 2022-08-11 | Sale | 42,000 0.0211% | $2.91 | $122,220 | -58.40% | |||
| 2022-07-18 | Sale | 7,500 0.0036% | $2.57 | $19,275 | -49.19% | |||
| 2022-07-14 | Sale | Chief Executive Officer | 150,000 0.0716% | $2.72 | $408,000 | -52.09% | ||
| 2022-05-13 | Sale | Chief Executive Officer | 125,000 0.0529% | $1.92 | $240,000 | -23.33% | ||
| 2022-04-18 | Sale | 7,500 0.0038% | $2.83 | $21,225 | -33.85% | |||
| 2022-03-16 | Sale | Chief Executive Officer | 81,823 0.0367% | $2.65 | $216,831 | -31.01% | ||
| 2022-02-14 | Sale | Chief Executive Officer | 90,000 0.045% | $3.74 | $336,600 | -39.01% | ||
| 2022-01-18 | Sale | director | 7,500 0.0037% | $4.07 | $30,525 | -41.25% | ||
| 2021-12-16 | Sale | Chief Executive Officer | 115,000 0.0613% | $5.22 | $600,300 | -50.70% | ||
| 2021-11-16 | Sale | Chief Executive Officer | 115,000 0.0583% | $8.04 | $924,600 | -67.77% | ||
| 2021-11-03 | Sale | director | 150,300 0.1049% | $17.32 | $2.6M | -79.03% | ||
| 2021-11-02 | Sale | director | 149,700 0.0772% | $15.75 | $2.36M | -82.93% | ||
| 2021-11-02 | Sale | director | 25,000 0.0131% | $16.01 | $400,250 | -82.93% | ||
| 2021-11-02 | Sale | director | 15,000 0.0074% | $15.00 | $225,000 | -82.93% |
Insider Historical Profitability
| Lewis Michael | 3610570 1.2394% | $0.90 | 2 | 1 | ||
| Wilmslow Estates Ltd | 10 percent owner | 3610570 1.2394% | $0.90 | 2 | 1 | |
| Musunuri Shankar | Chief Executive Officer | 2190073 0.7518% | $0.90 | 2 | 16 | <0.0001% |
| Sofinnova Venture Partners VIII, L.P. | 10 percent owner | 2085848 0.716% | $0.90 | 1 | 1 | |
| SPLIT ROCK PARTNERS II, LP | 10 percent owner | 1661495 0.5703% | $0.90 | 2 | 1 | <0.0001% |
Institutional Investor Ownership
| The Vanguard Group | $19.68M | 4.66 | 12M | -0.34% | -$66,201.88 | <0.0001 | |
| BlackRock | $6.23M | 1.48 | 3.8M | +2.87% | +$173,772.77 | <0.0001 | |
| Geode Capital Management | $5.27M | 1.25 | 3.21M | +9.68% | +$465,155.34 | <0.0001 | |
| Goldman Sachs | $4.28M | 1.01 | 2.61M | New | +$4.28M | <0.01 | |
| Millennium Management LLC | $3.16M | 0.75 | 1.93M | +368.6% | +$2.48M | <0.01 |